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ABSTRACT
Homeodomain (HD) transcriptional activities are
tightly regulated during embryogenesis and require
protein interactions for their spatial and temporal
activation. The chromatin-associated high mobility
group protein (HMG-17) is associated with transcrip-
tionally active chromatin, however its role in regulat-
ing gene expression is unclear. This report reveals a
unique strategy in which, HMG-17 acts as a molec-
ular switch regulating HD transcriptional activity.
The switch utilizes the Wnt/b-catenin signaling path-
way and adds to the diverse functions of b-catenin.
A high-affinity HMG-17 interaction with the PITX2 HD
protein inhibits PITX2 DNA-binding activity. The
HMG-17/PITX2 inactive complex is concentrated to
specific nuclear regions primed for active transcrip-
tion. b-Catenin forms a ternary complex with PITX2/
HMG-17 to switch it from a repressor to an activator
complex. Without b-catenin, HMG-17 can physically
remove PITX2 from DNA to inhibit its transcriptional
activity. The PITX2/HMG-17 regulatory complex acts
independently of promoter targets and is a general
mechanism for the control of HD transcriptional
activity. HMG-17 is developmentally regulated and
its unique role during embryogenesis is revealed by
the early embryonic lethality of HMG-17 homozy-
gous mice. This mechanism provides a new role for
canonical Wnt/b-catenin signaling in regulating HD
transcriptional activity during development using
HMG-17 as a molecular switch.
INTRODUCTION
The chromatin-associated high mobility group protein
(HMG-17) is a member of the HMGN family including
HMG-14 that bind to the nucleosome core particle,
without speciﬁcity for a DNA sequence (1). HMGN
proteins are expressed in the nucleus and cytoplasm (2,3)
and they regulate chromatin structure (4), histone
modiﬁcations (5) and the rates of transcription (6).
These factors are non-histone proteins that may act to
modify chromatin structure to generate a conformation
that facilitates and enhances transcription, replication and
repair (4). In the nucleus, HMGN proteins appear to
associate and dissociate regularly among nucleosomes and
reduces the compaction of chromatin ﬁber (3,7). Thus,
HMG molecules bind DNA transiently and continuously
move to other binding sites within the chromatin.
However, their interaction with chromatin is likely
mediated by binding other factors in a multiprotein
complex (1,8).
HMG-17 is expressed during early mouse embryogen-
esis throughout the entire embryo but is down regulated as
development proceeds. However, in some actively diﬀer-
entiating cell types or in kidney cells undergoing a
mesenchymal to epithelial transition, HMG-17 expression
is not decreased (9). Thus, HMG-17 may be required in
tissues or cells undergoing proliferation and diﬀerentiation
during organogenesis (10).
PITX2 is a ‘paired’ type homeodomain (HD) transcrip-
tional activator and its activity can be modulated through
protein interactions and phosphorylation (11–14). The
analyses of Pitx2
–/– homozygous knockout mice revealed
that Pitx2 is required for heart morphogenesis, develop-
ment of the mandibular and maxillary facial prominences,
tooth and pituitary development (15–18). For PITX2,
the C-terminal and HD regions of the protein have been
identiﬁed as sites for protein–protein interactions
(14,19–22). The canonical Wnt signaling pathway is one
mechanism where b-catenin and Lef-1 can independently
interact with PITX2 to increase its transcriptional activity
(22,23). Thus, it is becoming clear that diﬀerential
mechanisms for b-catenin regulated transcription occur
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major developmental event. Identifying these alternative
pathways is of major interest to elucidate new develop-
mental programs.
The regulated transcriptional activity of PITX2 through
its interaction with HMG-17, modulated by b-catenin
represents a new alternative Wnt/b-catenin signaling
pathway. We demonstrate a novel molecular mechanism
for the control of PITX2 HD transcription factor acti-
vation through its interaction with HMG-17. HMG-17
inhibits PITX2 DNA binding through an interaction with
the PITX2 HD. HMG-17 forms an inhibitory complex
with PITX2, which can be activated by canonical Wnt/
b-catenin signaling. HMG-17 and PITX2 co-localize to
chromatin structures in the nucleus. b-Catenin interacts
with PITX2 in the nucleus and de-represses the PITX2/
HMG-17 complex. This type of mechanism would allow
for the tight spatial and temporal expression of PITX2
target genes during embryogenesis.
MATERIALS AND METHODS
Yeast two-hybrid system
PITX2 was used as bait with a cDNA library to identify
interacting factors. PITX2A was cloned in the Gal4 DNA-
binding domain vector (pBD-Gal4 vector, Stratagene).
PITX2A, PITX2A C173, PITX2A C39 and PITX2A HD
were PCR ampliﬁed using primers with Sal1 sites and
inserted into the vector digested with Sal1. The library
contains cDNA prepared from one-day postnatal mouse
teeth (molars and incisors). The cDNAs are fused to
the Gal4 transactivation domain in the Stratagene two-
hybrid vector. This plasmid library contains 10
7 individual
cDNAs. The library was ampliﬁed in yeast. The recom-
binant library plasmids and the bait plasmid were
co-transformed into a reporter yeast strain (YRG-2).
This strain has the his3 and lacZ (b-galactosidase) genes
under control of a Gal4 responsive element. Yeast
transformed with the library (initially 10
6 transformants)
were selected for growth on auxotrophic medium lacking
histidine, in the presence of 15mM 3-AT. The yeast were
screened for expression of b-galactosidase (blue/white
screening with X-gal) to conﬁrm the interaction. The ﬁlter
lift assay was done according to the manufacturer’s
directions (Stratagene). Plasmids were isolated from the
yeast and used to retransform the YRG-2 yeast strain.
This eliminated the possibility of background genomic
mutations. Clones were further screened on tryptophan
and leucine minus plates. Strong positive clones were
identiﬁed and the cDNA sequence analyzed using
GenBank to determine the clone identity.
Expression andpurification of GST fusion proteins
The human PITX2A and C constructs were PCR
ampliﬁed from cDNA clones as described (12,24). The
PITX2, b-catenin and HMG-17 PCR products were cloned
into the pGex6P-2 GST vector (Amersham Pharmacia
Biotech) as previously described (12,24). All pGex6P-2
GST plasmids were conﬁrmed by DNA sequencing. The
plasmids were transformed into BL21 cells. Proteins were
isolated as described (19,24). All proteins were cleaved
from the GST moiety by PreScission protease (GE
HealthCare). Protein concentration was quantitated with
Bradford Reagent (BioRad Laboratories, Hercules, CA).
Proteins were examined by electrophoresis on denaturing
SDS–polyacrylamide gels, followed by Coomassie blue
staining (50% methanol, 10% acetic acid and 0.5%
Coomassie brilliant blue stain).
GST–PITX2 pull-down assays
Immobilized GST–HMG-17, GST–b-catenin and GST–
PITX2 fusion proteins were prepared as described above
and suspended in binding buﬀer (20mM HEPES pH 7.5,
5% glycerol, 50mM NaCl, 1mM EDTA, 1mM DTT,
with or without 1% milk and 400mg/ml of ethidium
bromide). Bacterially over-expressed and puriﬁed PITX2,
b-catenin or HMG-17 protein (75–400ng) were added to
5mg’s immobilized GST–HMG-17, GST–b-catenin, GST–
PITX2, GST–PITX2 truncated fusion proteins or GST,
respectively, in a total volume of 50ml, and incubated for
30min at 48C. The beads were pelleted and washed three
times with 100ml binding buﬀer. The bound proteins were
eluted by boiling in SDS-sample buﬀer and separated
on either 10% or 12.5% SDS–polyacrylamide gel or 15%
tricine gels. The experiment to analyze co-binding of
b-catenin and HMG-17 to PITX2 was performed by
adding puriﬁed b-catenin and HMG-17 to the appropriate
GST–PITX2 constructs. After incubation and extensive
washing the beads were divided into equal aliquots, run on
an SDS gel and probed with either b-catenin or HMG-17
antibodies. Thus, both HMG-17 and b-catenin were
present in the binding reactions. Puriﬁed PITX2, b-catenin
or HMG-17 proteins were analyzed in the western blot.
Following SDS gel electrophoresis, the proteins were
transferred to PVDF ﬁlters (Millipore), immunoblotted
and detected using the PITX2, b-catenin or HMG-17
antibody (Upstate) and ECL reagents from GE
HealthCare.
Westernblot assays
Expression of endogenous or transiently expressed PITX2,
b-catenin and HMG-17 proteins was demonstrated using
the PITX2 P2R10 antibody (25), HMG-17 and b-catenin
antibodies (Upstate). Approximately 10–40mg of trans-
fected cell lysates were analyzed in western blots.
Following SDS gel electrophoresis, the proteins were
transferred to PVDF ﬁlters (Millipore), immunoblotted
and detected using speciﬁc antibodies and ECL reagents
from GE HealthCare.
Electrophoretic mobility shift assay(EMSA)
Complementary oligonucleotides containing a PITX2-
binding site within the Dlx2 promoter with ﬂanking
partial BamHI ends were annealed and ﬁlled with Klenow
polymerase to generate
32P-labeled probes for EMSAs
as described (21). The sequence of the sense oligonucleo-
tide for probe Dlx TAATCC was 50-gatccGCTCAT
GCCTGTAATCCCAGCACTCAGGg-30 and antisense
50-gatccCCTGAGTGCTGGGATTACAGGCATGAGC
g-30 leaving the four base overhangs (lowercase letters)
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is underlined. Standard binding assays were performed
as previously described (12). A titration of the bacteria
expressed and puriﬁed HMG-17 protein was used in the
assays. The samples were electrophoresed, visualized and
quantitated as described previously, except quantitation of
dried gels was performed on the Molecular Dynamics
STORM PhosphoImager (21).
Expression and reporter constructs
Expression plasmids containing the cytomegalovirus
(CMV) promoter linked to the PITX2 cDNA were con-
structed in pcDNA 3.1 MycHisC (Invitrogen) (12,19,24).
Lef-1 and b-catenin S37A expression plasmids have been
previouslydescribed(26).HMG-17anddeletionconstructs
were prepared by PCR ampliﬁcation of the full-length
HMG-17 cDNA and cloned into the pcDNA3.1 MycHisC
vector. The Dlx2 promoter cloned into the luciferase vector
has been previously described (21). All constructs
were conﬁrmed by DNA sequencing. SV-40 or CMV
b-galactosidase reporter plasmids were co-transfected in all
experiments as a control for transfection eﬃciency. All
plasmids were double-banded CsCl puriﬁed.
HMG-17 siRNA constructs
Two HMG-17 short hairpin RNA (shRNA) constructs
were prepared using sequences downstream of the ATG in
the HMG-17 cDNA. HMG-17 shRNA1 was made by
annealing the sense oligo, 50-GATCCTCTGCGAGGTT
GTCTGCTATTCAAGAGATAGCAGACAACCTCGC
AGATCA-30 with the antisense oligo, 50-AGCTTGAT
CTGCGAGGTTGTCTGCTATCTCTTGAATAGCAG
ACAACCTCGCAGAG- 3 0. HMG-17 shRNA2 was
made using the sense oligo, 50-GATCCAAATGGAG
ATGCCAAAACATTCAAGAGATGTTTTGGCATCT
CCATTTTCA-30 and the antisense oligo, 50-AGCTTGA
AAATGGAGATGCCAAAACATCTCTTGAATGTTT
TGGCATCTCCATTTG-30. The 50 BamH1 and 30
HindIII sites are underlined and the hairpin loop is in
bold. The annealed oligos were cloned into the pSilencer
4.1-CMV neo siRNA expression vector (Ambion) digested
with BamH1 and HindIII per the manufacturer’s direc-
tions. The HMG-17 sequence is 70bp downstream of the
ATG in clone HMG-17 shRNA1 and 210bp downstream
of the ATG in HMG-17 shRNA2. This vector uses
the CMV promoter to drive expression of the transcript.
All constructs were conﬁrmed by DNA sequencing. All
plasmids were double-banded CsCl puriﬁed.
Immunocytochemistry
CHO cells were cultured in Dulbecco’s modiﬁed Eagle’s
medium (D-MEM) supplemented with 5% fetal bovine
serum (FBS) and penicillin/streptomycin seeded on
18mm 18mm microscope glass cover slips in 60mm
dishes after transfection by electroporation. CHO cells
were mixed with 10mg of expression plasmids pCMV–
PITX2A and MycHisC–HMG-17. CHO cells were elec-
troporated at 380V and 950 microfarads (mF) (Gene
Pulsar XL, Bio-Rad). CHO cells were fed 24h prior to
transfection. Transfected cells were incubated for 24h,
washed with PBS, ﬁxed in ice-cold acetone for 10min at
48C and air-dried.
Immunoﬂuorescent double staining was performed as
described (27). Fixed CHO cells were washed with PBS for
2 5min, incubated in 10% normal goat serum-PBS
30min at room temperature (RT), then incubated cells
with rabbit anti-PITX2at 48C overnight. After overnight
incubation, cells were rinsed by washing in PBS for
3 5min and cells were incubated with Alexa Fluor 555
goat anti-rabbit IgG 30min at 378C. Cells were washed
with PBS for 3 5min. To block binding of the rabbit
anti-PITX2 IgG of the secondary staining to the goat anti-
rabbit IgGs used in the ﬁrst round staining, the CHO cells
were incubated with rabbit IgG at 1:25 for 2h at RT.
Subsequently, the CHO cells were incubated with 1:300
rabbit anti-HMG17 (CHEMICON International, Inc.)
at 48C overnight, washed in PBS 3 5min and cells
were incubated with Alexa Fluor 488 goat anti-rabbit
IgG(H+L) (Molecular Probes, Invitrogen detection
technologies) for 30min at 378C. The cells were mounted
with VECTASHIELD Mounting Medium with DAPI
(Vector Laboratories, Inc. Burlingame, CA, USA) and
examined with a Zeiss Axiophot Fluorescent Microscope
using Axion4.3 Version software.
Confocal microscope analyses of endogenous Pitx2 and
HMG-17 protein expression in LS-8 cells was performed
as above with the following modiﬁcations. Cold acetone
ﬁxed LS-8 cells were washed with PBS for 2 5min,
incubated in 10% normal goat serum-PBS for 30min at
RT, incubated with mouse anti-Pitx2 IgG (Novus
Biologicals) at 1:100 dilution and rabbit anti-HMG-17
IgG (Chemicon, International, Inc.) at 1:300 dilution at
48C overnight. The cells were washed in PBS 3 5min
and incubated with Alexa Fluor 555 donkey anti-mouse
IgG (H&L) and Alexa Fluor 488 goat anti-rabbit IgG
(H&L) (Molecular Probes, Invitrogen detection technol-
ogies) for 30min at 378C. The cells were mounted with
Vectashield mounting medium (Vector Laboratories,
Inc.). Images were acquired using a Zeiss LSM510
confocal microscope.
Cell culture, transient transfections, luciferase and
b-galactosidase assays
CHO, C3H10T1/2 and LS-8 cells were cultured in
D-MEM supplemented with 5% or 10% FBS and
penicillin/streptomycin and transfected by electropora-
tion. Cultures were fed 24h prior to transfection,
resuspended in PBS and mixed with 2.5mg of expression
plasmids, 5mg of reporter plasmid and 0.5 mg of CMV or
SV-40 b-galactosidase plasmid. LiCl was added to the
appropriate cells after electroporation at a ﬁnal concen-
tration of 10mM. Electroporation of CHO cells was
performed at 380V and 950mF (Gene Pulser XL,
Bio-Rad), and C3H10T1/2 cells at 360V and 950mF.
LS-8 cells were transfected by electroporation as pre-
viously described (21). Transfected cells were incubated
for 24h in 60mm culture dishes and fed with 5% FBS and
D-MEM and then lyzed and assayed for reporter activities
and protein content by Bradford assay (Bio-Rad).
Luciferase was measured using reagents from Promega.
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Plus reagents (Tropix Inc.). All luciferase activities were
normalized to b-galactosidase activity.
Immunoprecipitation assay
Approximately 24h after cell transfection with PITX2 and
HMG-17, CHO cells were rinsed with 1ml of PBS, then
incubated with 1ml ice-cold RIPA buﬀer for 15min at
48C. Cells were harvested and disrupted by repeated
aspiration through a 25-gauge needle attached to a 1ml
syringe. The lysates were then incubated on ice for 30min.
Cellular debris was pelleted by centrifugation at 10000g
for 10min at 48C. An aliquot of lysate was saved for
analysis as input control. Supernatant was transferred to a
fresh 1.5ml microfuge tube on ice and precleared using the
mouse ExactaCruz F IP matrix (ExactaCruz F, Santa
Cruz Biotechnology) for 30min at 48C. Matrix was
removed by brief centrifugation and supernatant trans-
ferred to a new tube. An IP antibody–IP matrix complex
was prepared as per manufacturer’s instructions using
primary anti-HMG-17 antibody (UPSTATE). The IP
antibody–IP matrix complex was incubated with the pre-
cleared cell lysate at 48C for 12h. After incubation, the
lysate was centrifuged to pellet the IP matrix. The matrix
was washed two times with PBS and resuspended in 15ml
of ddH2O and 3ml6  SDS loading dye. Samples were
boiled for 5min and resolved on a 10% polyacylamide gel.
Western blotting was used with anti-PITX2 antibody and
HRP-conjugated rabbit ExactaCruz F reagent to detect
immunoprecipitated proteins.
Fluorescence polarization measurements ofDNA binding
and proteininteractions
Fluorescence polarization experiments were done with
a PanVera Beacon ﬂuorescence polarization system
(PanVera Corp.). 50-Fluoresceinated oligonucleotides
corresponding to the PITX2-binding site (bicoid
element), (Oligos Etc.), (50-F-TTAATCCCCCCCCGG
GATTAA-30), were self-annealed in 10mM sodium
cacodylate, pH 6.5, by heating to 908C followed by ﬂash
cooling to form a stem-loop structure with the bicoid
element (underlined). Oligonucleotide concentrations were
calculated and binding was assayed in a 100ml volume at
258C. The binding experiments contained the following:
65nM ﬂuoresceinated DNA (IT=230), and 1.0mg/ml
poly(d[I-C]) in HEPES-binding buﬀer (20mM HEPES,
pH 7.5, 5% glycerol, 50mM NaCl, 1mM EDTA, 1mM
DTT). Poly(d[I-C]) (Sigma) was included as a control for
nonspeciﬁc DNA binding. After each addition of protein,
samples were incubated in the Beacon instrument at 258C
for 30s before a measurement was taken. The 15s
incubation allowed equilibrium to be reached as pre-
viously described (28). Samples were excited at 490nm,
and emission was measured at 530nm.
The data of each binding isotherm were analyzed by
curve ﬁtting using KaleidaGraph software (Synergy
Software). Protein additions were stopped at  10-fold
over the calculated dissociation constants to ensure that
maximum binding was achieved. The following general
curve ﬁt equation was used to deﬁne the dissociation
constant (29):
mP ¼
mPi þ mP ½P 
ðKd þ½ P Þ
where mPi is the initial mP (millipolarization), mP the
overall change in mP and [P] is the protein concentration.
The following general curve ﬁt equation was used to
determine the Ki of HMG-17 (30):
a ¼
ðKd þ½ S Þ
ðKd
 ð1 þ½ I =KiÞþ½ S Þ
where a is the residual activity (mP mP/mP), Kd is the
previously determined Kd of PITX2, [S] is the concentra-
tion of PITX2 that was present for the Ki measurement
and [I] is the concentration of HMG-17.
Analysisof HMG-17–PITX2 HD interaction by surface
plasmonresonance (SPR)
SPR experiments were performed at 258C on a BIAcore
3000 (BIAcore AB). Thirteen thousand resonance units
(RU) of anti-GST antibody (BIAcore AB) were immobi-
lized simultaneously on two ﬂow cells on a CM5 sensor
chip using anti-GST antibody immobilization protocol
V1.0 provided by the manufacturer. GST–PITX2 HD and
GST (BIAcore AB) at the same concentration (10mg/ml)
were injected separately over the anti-GST surfaces
in running buﬀer (10mM potassium phosphate, pH 7.4,
150mM NaCl, 0.5mg/ml BSA and 0.005% surfactant
P-20). The amount of GST–PITX2 HD captured on the
sample ﬂow cell was 1950 RU. The other ﬂow cell with
GST captured (1600RU) serves as a reference surface.
Twofold linear dilution series (8–0.5nM) of HMG-17 in
the running buﬀer were injected over sample and reference
ﬂow cells at the same time for 8min at a ﬂow rate of
30ml/min. After dissociation with running buﬀer for
4min, the bound HMG-17 was removed with 30s pulse
of regeneration buﬀer (10mM potassium phosphate, pH
7.4, 500mM NaCl). All measurements were baseline
corrected by subtracting the sensorgram obtained with
reference surface and buﬀer blank (double referencing).
Data were globally ﬁtted to a 1:1 Langmuir-binding model
using BIAevaluation software (Version 4.1) to obtain the
association and dissociation rate constants (kon and koﬀ,
respectively). The dissociation constant (KD) was calcu-
lated from the kinetic parameters as KD=koﬀ/kon.
Chromatin immunoprecipitation analysis
The triple sequential ChIP assays were performed using
the ChIP Assay kit (Upstate) and as previously described
(31) except for the following modiﬁcations. LS-8 cells were
used and lysates were incubated ﬁrst with b-catenin
polyclonal rabbit IgG (Upstate) overnight at 48C. The
following day the samples were washed and eluted using
0.1% SDS, 30mM DTT and 100mM NaCl and incubated
at 378C for 30min. The samples were diluted 1:50 with
ChIP Dilution Buﬀer and incubated overnight with
HMG-17 monoclonal rabbit IgG (Upstate) at 48C. The
following day the samples were washed and eluted as
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(25) overnight at 48C. Two primers for amplifying the
b-catenin/HMG-17/Pitx2-binding site in the Dlx2 pro-
moter are as follows: sense starting at –716 to –696,
50-GGAGGGAACCTCAGAATCAG-30 and antisense at
–325 to –347, 50-ACATCTCTTGTCCAACTTCGCC-30.
PCR conditions include 588C annealing and 35 cycles,
input control contained 5% of the initial chromatin DNA.
All the PCR products were evaluated on a 2% agarose gel
in 1  TBE for appropriate size and conﬁrmed by
sequencing.
RESULTS
HMG-17 interacts withthe PITX2 HD
HMG-17 was identiﬁed as a PITX2 interacting partner
using the yeast two-hybrid assay. Over 500000 clones were
screened using an oral epithelial cell (LS-8 cells) library as
prey and the PITX2A full-length, HD and C-terminal tail
were used as the bait. A stringent screening process
identiﬁed 40 clones that grew on histidine/tryptophan/
leucine minus plates. After sequencing 17 were conﬁrmed
to be HMG-17. HMG-17 interacted with the PITX2A
full-length protein, PITX2 HD and the PITX2C-terminal
tail. Transformants containing the HMG-17 clone were
re-streaked on an SD agar plate without leucine,
trptophan and histidine. LacZ expression of the cotrans-
formants was determined by the ﬁlter lift assay (yeast two-
hybrid data not shown).
To map the PITX2 interaction region, GST-pull-down
experiments were performed using puriﬁed bacteria
expressed proteins. A schematic of the immobilized
GST-PITX2A wild type and truncated proteins are
shown in Figure 1A. The structure of the HMG-17
protein and Coomassie blue stained gel of the puriﬁed
HMG-17 protein used in the assays are shown in
Figure 1B. Immobilized PITX2 HD (GST-PITX2 HD)
bound the HMG-17 protein (Figure 1C). GST-PITX2
C173, which has the complete C-terminal tail deleted
bound HMG-17 (Figure 1C). HMG-17 bound to the
PITX28C-terminal tail (GST-PITX2 C173) and speciﬁ-
cally to the last C-terminal 39 residues (GST-PITX2 C39)
(Figure 1C). As a control, GST beads or the PITX2N
terminus did not bind the HMG-17 protein (Figure 1C,
data not shown). We have designated these two binding
sites in the PITX2 protein as HMG-17-binding domain
(BD) #1 and #2 (Figure 1A).
Because HMG-17 interacts with the PITX2 HD, which
confers DNA-binding activity, we asked if HMG-17
aﬀected the DNA-binding properties of PITX2. PITX2
speciﬁcally binds to the Dlx2 promoter and this element
(TAATCC) was used as the probe in the EMSA. HMG-17
is a small peptide (89 residues) and does not cause a large
shift in the probe band and only a small amount of HMG-
17/DNA complex is observed immediately above the free
probe (Figure 1D). HMG-17–DNA binding is transient
and may not be stable in these experiments (4). However,
HMG-17 inhibited PITX2A and PITX2C isoform (80ng)
DNA-binding activity (Figure 1D). PITX2A and PITX2C
are the major isoforms involved in embryogenesis and
have identical HDs and C-terminal tails (19,32). HMG-17
was titrated at 20, 40 and 60ng to 80ng of PITX2
isoforms and the higher HMG-17 concentration inhibited
over 90% of PITX2A and PITX2C binding to the Dlx2
promoter probe (Figure 1D).
b-catenin de-represses HMG-17 inhibition ofPITX2
transcriptional activity
CHO cells were co-transfected with PITX2A, HMG-17
and the full-length Dlx2 3276 luc promoter to determine if
HMG-17 regulated the transcriptional activity of
PITX2A. CHO cells do not endogenously express Pitx2
and only low levels of b-catenin (22). Therefore, CHO cells
were used in the assay without interference from
endogenous Pitx2 activity. The pluripotent C3H10T1/2
cells, CHO cells and LS-8 cells endogenously express
HMG-17 demonstrating the ubiquitous expression pattern
of this factor (Figure 2B) (4). PITX2A activated the Dlx2
promoter by  30-fold (Figure 2A). Co-expression of
PITX2A and HMG-17 revealed a 3-fold decrease in
PITX2A activation from 30-fold to 10-fold (Figure 2A).
We have previously shown that b-catenin interacts with
PITX2 to synergistically activate gene expression (22).
Furthermore, b-catenin directly interacts with the PITX2
HD to regulate PITX2 transcriptional activation (33).
We asked if b-catenin S37A (constitutively active form)
would regulate the HMG-17 repression of PITX2.
Co-transfection of PITX2A and b-catenin S37A
resulted in a 43-fold synergistic activation of the Dlx2
promoter (Figure 2A). Co-transfection of PITX2A,
HMG-17 and b-catenin S37A activated the Dlx2 promo-
ter by 65-fold compared to 10-fold activation for PITX2
and HMG-17 co-transfection (Figure 2A). The activity of
the PITX2/HMG-17 complex is switched from a repressor
to an activator in the presence of b-catenin (65-fold,
Figure 2A). The action of b-catenin was not cell speciﬁc
as b-catenin de-repressed the HMG-17 inhibition of
PITX2 in transfected C3H10T1/2 and LS-8 cells (data
not shown). A western blot demonstrates equal expression
of transfected PITX2, b-catenin and HMG-17
(Figure 2C).
Consistent with increased PITX2A transcriptional acti-
vation by transfected b-catenin, cells treated with LiCl
increased PITX2C activation of the Dlx2 promoter
(Figure 2D). HMG-17 repression is not PITX2 isoform
dependent as would be expected since both isoforms
contain identical HDs and C-terminal tails (19). LiCl is a
potent GSK-3 inhibitor and inhibits b-catenin phosphor-
ylation and stabilizes the pool of cellular b-catenin similar
to Wnt signaling (34). HMG-17 did not activate the Dlx2
promoter after LiCl treatment of CHO cells however,
PITX2C activation of the Dlx2 promoter in the presence
of HMG-17, increased from 10- to 37-fold after treatment
with LiCl (Figure 2D). The increase in PITX2C activation
with LiCl treatment and HMG-17 was less than the
activation by transfected b-catenin S37A with PITX2A
and HMG-17 observed in Figure 2A. This is presumably
due to the increased pool of b-catenin S37A from the
transfected plasmid compared to the endogenous b-catenin
pool stabilized by LiCl treatment. Furthermore, LiCl
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not activate the Dlx2 promoter at the levels of PITX2C
expression alone with LiCl due to the limited endogenous
b-catenin pool and exogenous HMG-17 (Figure 2D).
However, both methods of increasing b-catenin activity
reveal a role for b-catenin in de-repressing HMG-17
inhibition of PITX2. Similar results were observed in
LS-8 transfected cells (Figure 2E).
Figure 1. HMG-17 interacts with two regions of the PITX2 protein. (A) Schematic of the PITX2A protein and the N-terminal and C-terminal
truncated proteins. The location of the two HMG-17-binding domains (BD) in the PITX2 protein are shown. (B) Schematic of the HMG-17 protein;
NLS, nuclear localization signal; NBD, nucleosomal-binding domain; CHUD, chromatin-unfolding domain (4). The puriﬁed HMG-17 protein used
in the various assays was visualized by Coomassie blue staining. (C) GST–PITX2A protein pull-down assay with bacterial expressed and puriﬁed
HMG-17 protein (100ng). To demonstrate HMG-17 binding to PITX2A, PITX2A protein was incubated with puriﬁed HMG-17 protein. HMG-17
binds to the PITX2 homeodomain (HD) and this region is termed HMG-17 BD #1. HMG-17 binds to a region containing the C-terminal OAR
domain (conserved 14 residue motif), which is termed HMG-17 BD #2. As a control GST-beads were incubated with puriﬁed HMG-17 to
demonstrate the speciﬁcity of HMG-17 binding to the GST–PITX2A fusion proteins. (D) HMG-17 protein (20, 40 and 60ng) was incubated with the
Dlx2 promoter sequence containing a PITX2-binding element (TAATCC) as the radioactive probe in an electrophoretic mobility shift assay (EMSA).
HMG-17 did not bind in this assay to DNA however, PITX2A and PITX2C proteins (80ng) bound to the DNA. HMG-17 titration (20, 40 and
60ng) with 80ng of either PITX2A or PITX2C revealed that HMG-17 inhibited PITX2 binding in a dose-responsive manner. The EMSA
experiments were analyzed in 8% native polyacrylamide gels. The free and bound forms of DNA were quantitated using the Molecular Dynamics
STORM PhosphoImager. The free probe and bound DNA are indicated.
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transcriptional activity
We next asked if endogenous HMG-17 was repressing
PITX2 activation. Inhibition of endogenous HMG-17
expression by HMG-17 siRNA (siHMG-17) increased
PITX2C activation of the Dlx2 promoter from 33- to
45-fold (Figure 3A). A negative control (siNEG supplied
by Ambion), and siGADPH did not aﬀect the activity of
PITX2C in CHO cells (Figure 3A).
Western blot analyses were performed to demonstrate
reduced endogenous HMG-17 protein by HMG-17
siRNA. Endogenous HMG-17 protein is detected in
mock and PITX2 transfected lysates (Figure 3B, lanes 2
and 3). Transfected HMG-17 migrates slightly slower than
endogenous HMG-17 in the gel due to a myc/his tag on the
transfected protein (Figure 3B, lanes 4 and 5).
Interestingly, PITX2 stabilized both endogenous and
transfected HMG-17 (Figure 3B, compare lanes 4 and 5).
Endogenous HMG-17 was completely inhibited by
siHMG-17 expression (Figure 3B, lane 6). The siNEG
control had no eﬀect on endogenous HMG-17 expression
(Figure 3B, lane 7). As a loading control the western blot
was stripped and re-probed with the GAPDH antibody.
Similar levels of GAPDH were observed in all lanes
demonstrating that equal protein amounts were assayed
(Figure 3C). As another control a western blot demon-
strates that PITX2 and HMG-17 expression did not aﬀect
GAPDH expression. More importantly siNEG and
siHMG-17 did not aﬀect GAPDH expression demonstrat-
ing the speciﬁcity of these siRNAs (Figure 3D). siGADPH
inhibited endogenous GAPDH expression  50% after
only 24h (Figure 3D). It should be noted that all siRNA
experiments were assayed after 24h, and the complete loss
of HMG-17 protein after 24h suggests that it is a labile
protein. A western blot of transfected PITX2C demon-
strates PITX2C expression (Figure 3E).
PITX2 andHMG-17 co-localize in thecell nucleus
HMG-17 protein was visualized using FITC in the CHO
cell nucleus associated with chromatin structures and in
foci (Figure 4A), (35,36). There are two adjacent nuclei on
the left side of the panels. PITX2 was visualized with
Figure 2. The repression of PITX2 activity by HMG-17 is modulated by b-catenin. (A) CHO cells were transfected with the Dlx2 3.2kb luciferase
reporter gene (5mg) and co-transfected with CMV-PITX2, CMV-b-catenin S37A, CMV-HMG-17, or the CMV plasmid without PITX2, HMG-17 or
b-catenin (–) (2.5mg). To control for transfection eﬃciency, all transfections included the SV-40 b-galactosidase reporter (0.5mg). Cells were incubated
for 24h, and then assayed for luciferase and b-galactosidase activities. The activities are shown as mean fold activation compared to the Dlx2
promoter plasmids without PITX2, b-catenin or HMG-17 expression and normalized to b-galactosidase activity ( SEM from ﬁve independent
experiments). (B) HMG-17 is endogenously expressed in LS-8, C3H10T1/2 and CHO cells. (C) Western blot of transfected cell lysates (20mg);
PITX2A was detected using the PITX2 Ab (25) as previously described; b-catenin was detected using the antibody from Santa Cruz Biotech; and
HMG-17 was detected using an antibody from Chemicon International. The proteins were visualized using ECL reagents from Amersham.
Molecular weight markers are shown on the left of each blot. (D) Endogenous b-catenin de-repressed the PITX2/HMG-17 complex. CHO cells were
transfected as described above and transfected cells were treated without (–) and with (+) LiCl at a ﬁnal concentration of 10mM. The activities are
shown as mean fold activation compared to the Dlx2 promoter plasmid without PITX2 or HMG-17 expression and normalized to b-galactosidase
activity ( SEM from four independent experiments). (E) LS-8 oral epithelial cells were transfected as in panel D to determine if the activation was
cell dependent. The activities are shown as mean fold activation compared to the Dlx2 promoter plasmids without PITX2 or HMG-17 expression
and normalized to b-galactosidase activity ( SEM from eight independent experiments).
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with chromatin structures (Figure 4B). Merging the two
ﬂuorescent proteins reveals a strong overlap in their
nuclear localization (Figure 4C). DAPI staining reveals
the nuclear/chromatin structure (Figure 4D), and merging
of the DAPI stain with HMG-17 and PITX2 expression
correlates with these factors recruitment to nuclear
chromatin structures (Figure 4E).
Endogenous Pitx2 and HMG-17 expression was
observed in LS-8 nuclei (Figure 4H and I). Endogenous
Pitx2 expression appears diﬀusely throughout the nucleus
(Figure 4H), whereas HMG-17 expression is more
localized to small foci (Figure 4I). Merging the two
images reveals that Pitx2 is co-localized to nuclear regions
where HMG-17 resides (Figure 4J). While all HMG-17
appears to co-localize with Pitx2 not all Pitx2 staining
co-localizes with HMG-17.
Furthermore, HMG-17 expression occurs in the dental
and oral epithelial cells of an E14.5 molar tooth bud (data
not shown). The tooth epithelial speciﬁc expression of
HMG-17 directly overlaps that of PITX2 (37).
Specificity ofDNA bindingand the PITX2/HMG-17
interaction
The speciﬁcity of PITX2 and HMG-17 for DNA
were determined by binding to 50- ﬂuoresceinated oligo-
nucleotides corresponding to the PITX2-binding site
(bicoid element). Fluorescence polarization experiments
determined the binding curves for PITX2 and HMG-17
(Figure 5A and B). The calculated equilibrium dissocia-
tion constant, Kd is 129 17nM for PITX2 binding to the
bicoid element (Figure 5A). The calculated equilibrium
dissociation constant, Kd is 1.3 0.40mM for HMG-17
binding to the bicoid element (Figure 5B). Thus, HMG-17
has a low aﬃnity for DNA and correlates with
HMG-17 binding to DNA non-speciﬁcally.
HMG-17 binding to PITX2 was determined after PITX2
DNA binding reached equilibrium. A speciﬁc PITX2/
HMG-17 complex was identiﬁed by titrating HMG-17
protein to DNA bound PITX2. Surprisingly, HMG-17
addition to the PITX2/DNA complex resulted in decreased
polarization, demonstrating that HMG-17 was removing
PITX2 from the DNA (Figure 5C). These data correlate
with the EMSA data demonstrating that the PITX2/
HMG-17 complex cannot bind DNA. The inhibitory
constant (binding constant) of HMG-17 for PITX2 is,
Ki 105 5nM (Figure 5C). Thus, HMG-17 has 10-fold
higher aﬃnity for PITX2 than for DNA and HMG-17
has a higher binding aﬃnity for PITX2 than PITX2
has for DNA. HMG-17 physically interacts with the
PITX2 HD and this interaction releases PITX2 from
the DNA.
The interaction between HMG-17 and PITX2 HD
(HD only) was examined by real-time SPR-binding assay.
Figure 2. Continued.
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(Chi
2=0.61) (Figure 5D). The dissociation constant
(KD=3.04pM) obtained from the analysis indicated the
HMG-17–PITX2 HD interaction to be of high aﬃnity.
These data indicate a stronger aﬃnity of HMG-17 for
PITX2 than the polarization experiments due to binding
of the PITX2 HD peptide compared to the full-length
protein. Moreover, the kinetic parameters suggested that
this strong interaction was due to a fast complex
formation with association rate kon of (4.39 0.03)
 10
5M
–1s
–1, and a very stable complex with dissociation
rate koﬀ of (1.33 0.09)  10
–6s
–1. However, the stability
of the HMG-17/PITX2 HD complex could be easily
destroyed by slight increase of salt concentration. This is
Figure 3. Reduced endogenous HMG-17 protein increased PITX2 transcriptional activation. (A) CHO cells were transfected as in Figure 2 with the
Dlx2 3.2kb luciferase reporter (5mg). The cells were co-transfected with expression vectors, shRNA expression vectors or shRNA vectors alone (–)
(2.5mg). The activities are shown as mean fold activation compared to the Dlx2 promoter plasmids without PITX2, siRNA or HMG-17 expression
and normalized to b-galactosidase activity ( SEM from ﬁve independent experiments). (B) Western blots of endogenous and transfected HMG-17 in
CHO cells. Lane 1 is puriﬁed HMG-17 protein, lane 2 is endogenous HMG-17, lane 3 is endogenous HMG-17 after PITX2C transfection, lane 4 is
both endogenous and transfected HMG-17. The transfected HMG-17 migrates slightly slower in the gel due to a myc/his tag on the C-terminal tail
of the protein. Lane 5 is endogenous and transfected HMG-17 with transfected PITX2C, lane 6 demonstrates a complete inhibition of endogenous
HMG-17 expression by transfected HMG-17 siRNA. Lane 7 is endogenous HMG-17 with the transfected siNegative control and PITX2C. (C) The
western blot in panel B was stripped and re-probed with GAPDH antibody to demonstrate equal loading of the cell lysates. (D) Western blot of cell
lysates probed with the GAPDH antibody. (E) Western blot of transfected PITX2C with and without HMG-17 siRNA. The transfected PITX2C
protein migrates slightly slower in the gel due to a myc/his tag on the C-terminal tail of the protein.
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buﬀer, which contained 200mM or 500mM of NaCl,
removed bound HMG-17 from the HMG-17/PITX2
HD complex (Figure 5E). This indicated that HMG-17
and PITX2 HD bind to each other through ionic
interactions and the interaction can be regulated by salt
concentration. Therefore, strong interacting proteins
can modify PITX2 and HMG-17 ionic interactions.
The HMG-17/PITX2 interaction is measured diﬀerently
in the two assays, however both measurements
demonstrate a high aﬃnity association between the two
proteins.
PITX2/HMG-17/b-catenin complex
HMG-17 antibody (Ab) immunoprecipitates PITX2 only
in the presence of b-catenin. The previous experiments
demonstrated speciﬁc PITX2 and HMG-17 protein
Figure 4. PITX2 and HMG-17 co-localize in the nucleus. (A) HMG-17 expression was detected using an HMG-17 antibody and visualized with the
Alexa Fluor 555 goat anti-rabbit IgG. There are two adjacent nuclei on the left side of the panels. (B) PITX2 expression was detected with the PITX2
antibody (25) and the Alexa Fluor 488 goat anti-rabbit IgG(H+L) (Molecular Probes, Invitrogen detection technologies). (C) The corresponding
stained nuclei from panel A and B were merged to yield the image in panel C, demonstrating co-localization of HMG-17 and PITX2. (D) DAPI
staining of the nuclei in panels A–C, demonstrating intact nuclei. (E) Merging of panels A, B and C showing the DAPI stain overlaps with HMG-17
and PITX2 staining. (F) Negative control or secondary only antibody for Alexa Fluor 555 goat anti-rabbit IgG and (G) is the negative control for
secondary only antibody using the Alexa Fluor 488 goat anti-rabbit IgG. (H) Confocal image ( 40) of endogenous Pitx2 expression in LS-8 nuclei
and (I) endogenous HMG-17 expression. (J) Merged images of Pitx2 and HMG-17 expression.
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co-immunoprecipitated a PITX2/HMG-17 complex
(Figure 6A). A band was detected on longer exposure
times indicating that an interaction occurred between
PITX2 and HMG-17. This weak interaction could
correspond to the HMG-17 interaction with the
PITX2C-terminal tail as revealed in the GST-pull-down
experiments in Figure 1 or due to low levels of endogenous
b-catenin in the cells. These results are often observed
when the Ab cannot recognize an epitope buried in
a protein complex. However, when b-catenin was
co-expressed with PITX2 and HMG-17 the HMG-17 Ab
immunoprecipitated PITX2 suggesting that the complex
formed between these three proteins caused a conforma-
tional change allowing the Ab to recognize the HMG-17
protein (Figure 6A). As a control the HMG-17 Ab does
not recognize b-catenin in a western blot (data not
shown). Because b-catenin is a high-molecular weight
protein ( 89KDa), its interaction with PITX2 may
displace or reposition HMG-17 and allow the HMG-17
Ab to recognize it in the complex.
GST-pull-down assays provide an alternative method to
identify a PITX2/HMG-17/b-catenin complex. Immobi-
lized GST–PITX2A, GST–PITX2 HD and GST–PITX2
C173 were incubated with both HMG-17 (75ng) and
b-catenin (400ng) in one reaction (protein concentrations
were adjusted to equal similar amounts of protein
molecules) and after incubation and extensive washing
the reaction was divided into two aliquots, each aliquot
resolved separately on a polyacrylamide gel. One western
blot was probed using the HMG-17 antibody (Figure 6B).
As controls, GST–PITX2A alone and GST–PITX2A
incubated with only b-catenin did not produce an
HMG-17 protein band (Figure 6B). However, HMG-17
bound to PITX2A in the presence of b-catenin
(Figure 6B). HMG-17 bound to PITX2 HD and
PITX2A C173 demonstrating that HMG-17 binds to
both regions of PITX2 in the presence of b-catenin.
The second western blot revealed b-catenin binding to
PITX2A and the PITX2A HD in the presence of HMG-17
(Figure 6C). However, b-catenin did not bind to the
PITX2C-terminal tail and is speciﬁc only for the HD.
Figure 5. Binding isotherms and surface plasmon resonance (SPR) analysis of HMG-17/PITX2 interaction. Millipolarization (mP) is plotted against
the concentration of PITX2 and HMG-17 or both binding to ﬂuoresceinated oligodeoxynucleotides (F-bicoid DNA) in HEPES-binding buﬀer.
(A) PITX2 binding to F-bicoid DNA. (B) HMG-17 binding to F-bicoid DNA. (C) HMG-17 binding to DNA bound PITX2. (D) SPR-binding assay.
HMG-17at indicated concentrations was injected over immobilized PITX2 HD (HD, homeodomain) (GST-tagged) at a ﬂow rate of 30 ml/min. After
8min of injection (indicated by the arrow), the HMG17/PITX2 HD complex was washed with running buﬀer for 4min. Shown here are overlay of
baseline-adjusted sensorgrams (red jagged lines) and ﬁtted curves (black smooth lines) using 1:1 Langmuir-binding model. Kinetic rate constants
kon=(4.39 0.03) 10
5M
–1s
–1 and koﬀ=(1.33 0.09) 10
–6s
–1 were derived from the ﬁtting, and the dissociation constant KD of 3.04pM
(KD=kon/koﬀ) was obtained. (E) Dissociation of HMG17–PITX2 HD complex by salt. HMG17 (128nM) was injected over the PITX2 HD surface (i)
for 8min (ii), and followed by 4min wash with running buﬀer (iii). After regeneration with two consecutive 30s pulses of buﬀers containing
200mM (iv) and 500mM of NaCl (v), bound HMG17 was removed from the HMG17/PITX2 HD complex. RU, resonance units. Data are one
representative of two experiments.
472 Nucleic Acids Research, 2008, Vol. 36, No. 2Figure 6. PITX2, HMG-17 and b-catenin form a complex. (A) Co-immunoprecipitation (IP) experiments demonstrate a PITX2/HMG-17/b-catenin
complex in CHO cells. PITX2A, HMG-17 and/or b-catenin (2.5mg) were transfected into CHO cells. Cell lysates were incubated with HMG-17
antibody and the IP complex was isolated and resolved on a 10% SDS–polyacrylamide gel and probed for PITX2 using the PITX2 Ab. The
HMG-17 antibody was unable to immunoprecipitate the PITX2/HMG-17 complex. Co-expression of b-catenin with PITX2 and HMG-17 allowed
the HMG-17 antibody to recognize the PITX2/HMG-17/b-catenin complex and precipitated the complex. HMG-17 Ab does not bind to b-catenin.
The proteins were visualized using ECL reagents from Amersham. (B) PITX2A, HMG-17 and b-catenin complex formation by puriﬁed proteins.
GST–PITX2A and truncated PITX2A protein pull-down assay with bacterial expressed and puriﬁed HMG-17 (75ng) and b-catenin proteins
(400ng). Binding reactions contain both HMG-17 and b-catenin and after incubation the reactions were divided into two equal aliquots and resolved
on separate 10% SDS–polyacrylamide gels and transferred to PVDF membranes. One aliquot was probed for HMG-17 interactions using the
HMG-17 antibody. HMG-17 interacted with the PITX2 HD and C-terminal tail in the presence of b-catenin. (C) The duplicate aliquot was probed
for b-catenin interactions using the b-catenin antibody. b-catenin interacted with the PITX2 HD but not the C-terminal tail. These results
demonstrate that both HMG-17 and b-catenin bind to the PITX2 HD as a complex. As a control GST-beads were incubated with puriﬁed HMG-17
and b-catenin to demonstrate the speciﬁcity of binding to the GST–PITX2A fusion proteins. (D) GST-b-catenin was immobilized on beads and
incubated with HMG-17 to demonstrate that these two proteins do not physically interact. Addition of PITX2 C173 protein to GST-b-catenin and
HMG-17 demonstrated that HMG-17 interacts with PITX2 bound to b-catenin. Furthermore, PITX2 C173 interacts with b-catenin and addition
of HMG-17 increases the PITX2 C173 interaction with b-catenin. The proteins were visualized using ECL reagents from Amersham. Molecular
weight markers are noted. (E) Triple sequential ChIP using b-catenin Ab ﬁrst, followed by HMG-17 Ab and PITX2 Ab immunoprecipitations.
The Dlx2 primers produced the correct PCR product from the triple antibody IP (lane 2), Dlx2 primer only control (lane 3), Dlx2 primers with
chromatin input (lane 4), unrelated control primers with the triple IP chromatin (lane 5) and control primers with input control (lane 6). All bands
were sequenced to conﬁrm their identity.
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b-cateninwouldbepulleddownbyHMG-17bindingtothe
PITX2C-terminal tail. GST–pull downs and IP assays did
not detect a b-catenin/HMG-17 complex (data not shown).
While it is possible HMG-17 and b-catenin bind to PITX2
separately in these assays, excess amounts of HMG-17 and
b-catenin were added to each reaction with a limited
amount of immobilized PITX2. If the proteins were
binding separately we would not expect the high levels of
binding by each protein to PITX2 when both are present.
GST–b-catenin was immobilized on beads and did not
interact with puriﬁed HMG-17 protein (Figure 6D).
However, when PITX2 protein was added to the binding
reaction, HMG-17 bound to PITX2 C173 (does not
contain the C-terminal tail), which bound to b-catenin.
As expected PITX2 C173 bound to b-catenin and
interestingly addition of HMG-17 to the binding reaction
increased PITX2 C173 binding to b-catenin (Figure 6D).
Thus, HMG-17 appears to facilitate the interaction
between PITX2 and b-catenin. These data correlate with
the IP data to demonstrate a PITX2/HMG-17/b-catenin
complex forms by binding to the PITX2 HD.
A triple sequential ChIP assay demonstrates that
the Pitx2/HMG-17/b-catenin ternary complex resides on
the Dlx2 promoter chromatin. LS-8 cells were used in the
ChIP assay as these cells endogenously express all three
factors. The ﬁrst ChIP assay used the b-catenin antibody,
followed by the HMG-17 antibody and then the PITX2
antibody. After the last IP with the PITX2 antibody, the
Dlx2 promoter chromatin was ampliﬁed by PCR using
primers speciﬁc for the Dlx2 promoter ﬂanking a PITX2-
binding site. The primers ampliﬁed a 390bp product from
the triple antibody IP (Figure 6E, lane 2). As a control the
Dlx2 primers only did not produce a PCR product,
however the primers did produce the correct size band
from the input chromatin (Figure 6E, lane 4). Control
primers to an unrelated gene did not produce a product
from the triple IP chromatin (Figure 6E, lane 5). The
control primers did work with the input chromatin
(Figure 6E, lane 6). Thus, the endogenous complex of
Pitx2/HMG-17/b-catenin binds to the Dlx2 promoter
in vivo. These data correlate with the IP data to
demonstrate a PITX2/HMG-17/b-catenin complex forms
by binding to the PITX2 HD.
DISSCUSSION
HMG-17 isanovel embryonic regulator ofHD
transcriptional activity modulated by b-catenin
HMG-17 is a member of the HMG genes whose
expression is restricted to embryonic tissues and reduced
in adult tissues (10). It is expressed in a variety of tissues
that correlate with Pitx2 expression (10,25). HMG-17 is
an acetylated non-histone chromosomal protein that acts
to unfold the higher order chromatin structure to enhance
transcription (38). In the absence of transcription,
HMG-17 is released from chromatin and accumulates in
interchromatin clusters. Thus, HMG-17 intranuclear
distribution may be related to the transcriptional activity
of the cell (36). HMG-17 does not bind to consensus
chromatin sequences but is associated with other proteins
(1). These protein complexes may regulate the dynamic
organization of HMG-17 in the nucleus and direct the
proteins to speciﬁc sites in chromatin. HMG-17 appears to
move rapidly and constantly throughout the entire nucleus
and is associated with other proteins to form a multi-
protein complex (1). Thus, the intracellular traﬃcking and
chromatin targeting of HMG-17 may be regulated by
proteins interacting with HMG-17 (1). Our data corrob-
orates these ﬁndings and demonstrates that HMG-17
forms a complex with PITX2at chromatin structures.
Clearly, mechanisms must exist that direct HD transcrip-
tion factors to the sites of active transcription in the
nucleus. A simple diﬀusion strategy will not provide
concentrated transcription factors to sites speciﬁc for the
rapid increase in gene expression required for normal
embryo development.
Histone proteins have been well deﬁned as modulators
of transcription and play major roles in remodeling
chromatin and interactions with HMGN proteins.
Chromatin unfolding is facilitated by speciﬁc interactions
between the C-terminal of HMG-17 and the N-terminal
of histone H3 (39). Furthermore, HMGN proteins
may compete with histone H1 proteins for binding to
the chromatin, which would play a role in regulating the
structure and activity of the chromatin ﬁber (7). HMG
proteins alter the local structure of DNA or chromatin by
inducing a conformation that facilitates the binding of
speciﬁc regulatory factors (4,8). Thus, it is possible that
HMG-17 associates with the spatial organization of gene
expression within eukaryotic nuclei (40).
The HMG domain of Sox proteins can interact with
several transcription factors directly through their DNA-
binding domains (41). Curiously, detection of the HMG-
domain interacting factors by immunoprecipitation was
fairly weak. This weak interaction was supported by
moderate increases in salt concentrations that produced
strong reductions in the amounts of co-precipitated
partner protein (41). Furthermore, these interactions
were not stable under electrophoretic mobility shift
conditions. These data correlate with our data except
that we have identiﬁed a ternary complex containing
b-catenin that appears to stabilize the complex. The
contact between the Sox HMG domain and DNA-binding
domains of other transcription factors are weak, con-
versely we have demonstrated a strong interaction
between PITX2 and HMG-17. However, we have shown
that the PITX2/HMG-17 complex can be easily disso-
ciated by slight increases in salt concentrations. Thus, the
HMG-17 interaction with PITX2 is reversible and
provides a mechanism to change interaction partners
in solution as proposed for the Sox HMG domain (41).
This provides a mechanism for changes in HMG-17
binding to PITX2 to functionally change its activity in
response to other factors interacting with PITX2.
The inactive PITX2/HMG-17 complex would be con-
centrated at sites of active transcription as shown for
HMG-17. Upon Wnt signaling b-catenin would form
a ternary complex with PITX2/HMG-17 and switch this
complex to a highly active form. We speculate that
b-catenin binding to the PITX2/HMG-17 complex causes
474 Nucleic Acids Research, 2008, Vol. 36, No. 2a conformational change in HMG-17 that allows for the
PITX2 HD to recognize its DNA target sequence and
promotes the association of a higher ordered chromatin-
associated transcription complex. Previous reports have
demonstrated that HMG-17 acts as a transcriptional
facilitator or coactivator by unfolding the higher order
chromatin structure allowing transcription factors access
to the DNA (35,36). These data support our results
demonstrating an increase in transcription when the
ternary complex of PITX2, HMG-17 and b-catenin are
all present, and HMG-17 in this protein complex can then
facilitate RNA polymerase II interaction with the DNA
and overcome the repressive activity of the chromatin
ﬁber. We have proposed a model for the interaction of
PITX2 with HMG-17 and conversion of a repressor
complex to an activator dependent on canonical Wnt
signaling and b-catenin interaction (Figure 7). Without
Wnt signaling, b-catenin is degraded and PITX2 com-
plexes with HMG-17 in an inactive form. Wnt signaling
allows b-catenin translocation to the nucleus where it
complexes with PITX2 and HMG-17 to yield an active
transcriptional complex. When Wnt signaling is oﬀ and
nuclear b-catenin is reduced, HMG-17 inactivates PITX2
(Figure 7). This interaction would tightly control
the transcriptional activity of PITX2. Clearly other
chromatin-associated factors may play a role in this
multi-protein complex however, the major players in this
novel pathway are PITX2, HMG-17 and b-catenin.
HMG-17 appears to be a major regulator of the timing
of early embryonic development in the mouse (42). The
early embryonic lethality of the HMG-17
–/– homozygous
mice support the role of HMG-17 as a regulator of early
embryonic development.
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